On November 25th, baiyunshan ph (600332.SH) announced that its controlling subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (referred to as "Tianxin Pharmaceutical"), has received the "Pharmaceutical Registration Certificate" issued by the National Medical Products Administration for Cefdinir Granules (50mg).
Cefdinir Granules belong to the third generation cephalosporin antibiotics, mainly working by inhibiting the synthesis of bacterial cell walls to exert bactericidal effects. It is a broad-spectrum antibiotic that was approved for market in China in 2002. It is suitable for treating infections caused by strains sensitive to cefdinir, including Staphylococcus, Streptococcus, Pneumococcus, Enterococcus, Proteus, Neisseria gonorrhoeae, Katamorpha bacteria, Escherichia coli, Klebsiella, Proteus vulgaris, Hemophilus influenzae, among others, making it an antibiotic suitable for both adults and children.
